Table 1 Characteristics of datasets from Moorfields Eye Hospital (MEH) and Newcastle Eye Centre (NEC).

From: Dual site external validation of artificial intelligence-enabled treatment monitoring for neovascular age-related macular degeneration in England

  

MEH

(n = 259)

NEC

(n = 262)

Sex

Female

166 (64.1%)

161 (61.5%)

Male

93 (35.9%)

101 (38.5%)

Laterality

Left

120 (46.3%)

122 (46.6%)

Right

139 (53.7%)

140 (53.4%)

Ethnicity recorded in EMR

White

171 (66.0%)

243 (92.7%)

Asian

29 (11.2%)

1 (0.4%)

Redacted

39 (15.1%)

0 (0.0%)

Unknown

20 (7.7%)

18 (6.9%)

Diabetic status in EMR

Diabetes diagnosis recorded

10 (3.9%)

49 (18.7%)

IVI agent

Aflibercept

259 (0.0%)

238 (90.8%)

Ranibizumab

0 (0.0%)

24 (9.2%)

VA in ETDRS letters, median (IQR)

65 (50–75)

67 (55–74)

Age, median (IQR)

83 (75–86)

81 (76–85)

Prior treatment interval in weeks, median (IQR)

8 (6–9)

8 (6–8)

  1. IVI Intravitreal Injection, VA Visual Acuity, ETDRS Early Treatment of Diabetic Retinopathy Study, IQR Interquartile Range, EMR Electronic Medical Record.